The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a study of adjunctive atorvastatin for restoring normal EF in hypercholesterolemic (low-density lipoprotein cholesterol >120 mg per 100 ml) sildenafil non-responders, the atorvastatin group had significantly greater improvements in all International Index of Erectile Function (IIEF)-5 questions and the global efficacy question.16”
From Treatment Strategy for Non-Responders to PDE5 Inhibitors (2013) · cites this paper as [16]
In the citing paper
“Several studies have revealed that the correction of hyperlipidemia improves the response to PDE5 inhibitors in hypercholesterolemic men with ED who were not initially responsive to PDE5 inhibitors.”
From Treatment Strategy for Non-Responders to PDE5 Inhibitors (2013) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study
Feldman, H. A., Goldstein, I., Hatzichristou, D. G., Krane, R. J., & McKinlay, J. B. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)34871-1 · Cited by 5,074
Research works printed but not linked: 40
- Laumann EO, Paik A, Rosen RC . Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537–544. · DOI · Paper page
- Safarinejad MR . Prevalence and risk factors for erectile dysfunction in a population-based study in Iran. Int J Impot Res 2003; 15: 246–252. · DOI
- Aytaç IA, McKinlay JB, Krane RJ . The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50–56. · DOI · Paper page
- McKinlay JB . The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000; 12 (Suppl 4): S6–11. · DOI · Paper page
- McMahon CG, Samali R, Johnson H . Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. J Urol 2000; 164: 1192–1196. · DOI
- Brisson TE, Broderick GA, Thiel DD, Heckman MG, Pinkstaff DM . Vardenafil rescue rates of sildenafil nonresponders: objective assessment of 327 patients with erectile dysfunction. Urology 2006; 68: 397–401. · DOI
- Seftel AD . Challenges in oral therapy for erectile dysfunction. J Androl 2002; 23: 729–736. · DOI
- Barada J . Successful salvage of sildenafil (Viagra) failures: benefits of patient education and rechallenge with sildenafil. Int J Impot Res 2001; 13 (Suppl 4): S49.
- Jiann BP, Yu CC, Su CC, Huang JK . Rechallenge prior sildenafil nonresponders. Int J Impot Res 2004; 16: 64–68. · DOI
- Rendell MS, Rajfer J, Wicker PA, Smith MD . Sildenafil for treatment of erectile dysfunction in men with diabetes. JAMA 1999; 281: 421–426. · DOI
- Safarinejad MR . Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. J Diabetes Complications 2004; 18: 205–210. · DOI
- Guay AT, Perez JB, Jacobson J, Newton RA . Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 2001; 22: 793–797. · DOI · Paper page
- Safarinejad MR . Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a double-blind, placebo controlled, randomized study. J Urol 2009; 181: 252–258. · DOI
- Safarinejad MR, Kolahi AA, Ghaedi G . Safety and efficacy of sildenafil citrate in treating erectile dysfunction in patients with combat-related post-traumatic stress disorder: a double-blind, randomized and placebo-controlled study. BJU Int 2009; 104: 376–383. · DOI
- Safarinejad MR . Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study. Int J Impot Res 2006; 18: 550–558. · DOI
- Safarinejad MR, Hosseini SY . Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol 2008; 179: 1066–1071. · DOI
- Doğru MT, Başar MM, Simşek A, Yuvanç E, Güneri M, Ebinç H et al. Effects of statin treatment on serum sex steroids levels and autonomic and erectile function. Urology 2008; 71: 703–707. · DOI
- Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ . Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43: 179–184. · DOI
- Kugiyama K, Ohgushi M, Sugiyama S, Murohara T, Fukunaga K, Miyamoto E et al. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Circ Res 1992; 71: 1422–1428. · DOI
- Chang ST, Chu CM, Hsu JT, Lin PC, Shee JJ . Surveillance of cardiovascular risk factors for outpatients in different erectile dysfunction severity. Int J Impot Res 2009; 21: 116–121. · DOI
- Eaton CB, Liu YL, Mittleman MA, Miner M, Glasser DB, Rimm EB . A retrospective study of the relationship between biomarkers of atherosclerosis and erectile dysfunction in 988 men. Int J Impot Res 2007; 19: 218–225. · DOI
- Schouten BW, Bohnen AM, Bosch JL, Bernsen RM, Deckers JW, Dohle GR et al. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study. Int J Impot Res 2008; 20: 92–99. · DOI
- McFarlane SI, Muniyappa R, Francisco R, Sowers JR . Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002; 87: 1451–1458. · DOI · Paper page
- Castro MM, Rizzi E, Rascado RR, Nagassaki S, Bendhack LM, Tanus-Santos JE . Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. Eur J Pharmacol 2004; 498: 189–194. · DOI
- Morelli A, Chavalmane AK, Filippi S, Fibbi B, Silvestrini E, Sarchielli E et al. Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation. J Sex Med 2009; 6: 91–106. · DOI
- Hong SK, Han BK, Jeong SJ, Byun SS, Lee SE . Effect of statin therapy on early return of potency after nerve sparing radical retropubic prostatectomy. J Urol 2007; 178: 613–616. · DOI
- Saltzman EA, Guay AT, Jacobson J . Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol 2004; 172: 255–258. · DOI
- Herrmann HC, Levine LA, Macaluso Jr J, Walsh M, Bradbury D, Schwartz S et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med 2006; 3: 303–308. · DOI
- NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83–90. · DOI · Paper page
- Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A . The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile function. Urology 1997; 49: 822–830. · DOI · Paper page
- Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM . Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319–326. · DOI
- Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S . Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation 2004; 110: 856–861. · DOI
- Bank AJ, Kelly AS, Kaiser DR, Crawford WW, Waxman B, Schow DA et al. The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction. Vasc Med 2006; 11: 251–257. · DOI
- Puddu P, Puddu GM, Muscari A . HMG-CoA reductase inhibitors: is the endothelium the main target? Cardiology 2001; 95: 9–13. · DOI
- Carvajal A, Macias D, Sáinz M, Ortega S, Martín Arias LH, Velasco A et al. HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems. Drug Saf 2006; 29: 143–149. · DOI
- Jackson G . Simvastatin and impotence. Br Med J 1997; 351: 31. · DOI
- Boyd IW . Comment: HMG-CoA reductase inhibitor-induced impotence. Ann Pharmacother 1996; 30: 1199. · DOI
- Solomon H, Samarasinghe YP, Feher MD, Man J, Rivas-Toro H, Lumb PJ et al. Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract 2006; 60: 141–145. · DOI
- Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990; 86: 228–234. · DOI · Paper page
- Acharya UR, Kannathal N, Sing OW, Ping LY, Chua T . Heart rate analysis in normal subjects of various age group. Biomed Eng Online 2004; 3: 24. · DOI
Cited by
Gupta, B. P. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.440 · Cited by 312
Treatment Strategy for Non-Responders to PDE5 Inhibitors
Park, N. C., Kim, T. N., & Park, H. J. (2013) · The World Journal of Men's Health · doi:10.5534/wjmh.2013.31.1.31 · Cited by 41
Metadata
- Authors
- Dadkhah, F., Safarinejad, M. R., Asgari, M. A., Hosseini, S. Y., Lashay, A., & Amini, E.
- Venue
- International Journal of Impotence Research
- Published
- 2009-10-29
- Volume
- 22
- Issue
- 1
- Pages
- 51-60
- ISSN
- 0955-9930
- 1476-5489
- Cited by
- 50
- References
- 1
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.